Q1 results beat plan; EPS raised to high end of guidance
Guidance tone
Solventum's Q1 results exceeded expectations, driven by strong commercial execution and new product launches. Management reiterated full-year guidance while providing color on a significant ERP-driven Q2 sales pull-forward and continued portfolio optimization. Q1 organic growth 2.1% beat expectations, led by volume; EPS of $1.48 up 11%.
Solventum's Q1 results exceeded expectations, driven by strong commercial execution and new product launches. Management reiterated full-year guidance while providing color on a significant ERP-driven Q2 sales pull-forward and continued portfolio optimization. Q1 organic growth 2.1% beat expectations, led by volume; EPS of $1.48 up 11%.
Guidance tone
Q1 organic growth 2.1% beat expectations, led by volume; EPS of $1.48 up 11%.
Full-year EPS guidance raised to high end of $6.40-$6.60 range while maintaining top-line and margin guidance.
Expecting over $100M sales pull-forward into Q2 from Q3 ERP cutover; will be reversed in Q3.
Management sees AI as a helpful tool for autonomous coding, differentiating on data, rules, and rigor. They report growing traction in outpatient and inpatient settings, with compelling economics for customers, and expect up to 50% of customers to adopt autonomous coding during the LRP period.
Management expresses confidence about hitting LRP targets, with a robust new product pipeline, strong commercial execution, and continued margin expansion despite headwinds.
Management repeatedly emphasized momentum, execution, and faster-than-expected progress toward long-range targets, while maintaining full-year guidance.
“we are estimating over 100 million additional sales in Q2 as we're working with our customers and distributors to advance orders before we begin our Q3 cutover of ERPs in the US and Canada.”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| EPS | FY2026 | $6.40–$6.60 | $6.50 | MAINTAINED |